|
270 Companies |
|
374 Products |
|
374 Products |
|
160 Mechanisms of Action |
|
39 Trials |
|
5519 News |
|
| «12345678910111213...110111» |
- | leuprolide acetate for depot suspension / Generic mfg.
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: Effect of Short Term Ovarian Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess (clinicaltrials.gov) - Jul 19, 2018
P1, N=0, Withdrawn, Sponsor: University of Virginia
N=20 --> 0 | Trial completion date: Jun 2020 --> Jul 2018 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2019 --> Jul 2018
- | Trial completion date, Trial primary completion date: Muslim Americans Reaching for Health and Building Alliances (MARHABA): Patient Navigation Intervention to Increase Breast and Cervical Cancer Screening Among Muslim Women in New York City (clinicaltrials.gov) - Jul 19, 2018
P=N/A, N=540, Recruiting, Sponsor: New York University School of Medicine
N=20 --> 0 | Trial completion date: Jun 2020 --> Jul 2018 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2019 --> Jul 2018 Trial completion date: Aug 2018 --> Sep 2019 | Trial primary completion date: Jun 2018 --> Sep 2018
- | Trial completion, Enrollment change: SLNM/OSNA: SLNM in Endometrial Cancer Combined With OSNA (clinicaltrials.gov) - Jul 18, 2018
P=N/A, N=58, Completed, Sponsor: Charles University, Czech Republic
Trial completion date: Aug 2018 --> Sep 2019 | Trial primary completion date: Jun 2018 --> Sep 2018 Recruiting --> Completed | N=31 --> 58
- | Trial completion, Trial completion date, Trial primary completion date: PACT: Protect and Connect: Couple HIV Prevention for Drug Involved Male Offenders (clinicaltrials.gov) - Jul 18, 2018
P=N/A, N=480, Completed, Sponsor: Columbia University
Recruiting --> Completed | N=31 --> 58 Recruiting --> Completed | Trial completion date: Jul 2017 --> Sep 2017 | Trial primary completion date: Jul 2017 --> Sep 2017
- | clomifene citrate / Generic mfg.
Trial completion, Trial completion date: Clomiphene Citrate for the Treatment of Low Testosterone Associated With Chronic Opioid Pain Medication Administration (clinicaltrials.gov) - Jul 17, 2018
P2, N=13, Completed, Sponsor: Weill Medical College of Cornell University
Recruiting --> Completed | Trial completion date: Jul 2017 --> Sep 2017 | Trial primary completion date: Jul 2017 --> Sep 2017 Active, not recruiting --> Completed | Trial completion date: Jun 2017 --> Nov 2017
- | Nexplanon (etonogestrel implant) / Organon
Trial completion: vMICROb: Long-Acting Progestin Contraception and the Vaginal Microbiome (clinicaltrials.gov) - Jul 17, 2018
P=N/A, N=28, Completed, Sponsor: Boston Medical Center
Active, not recruiting --> Completed | Trial completion date: Jun 2017 --> Nov 2017 Active, not recruiting --> Completed
- | Trial completion, Enrollment change, Trial completion date, Trial primary completion date, HEOR: Sexual Functioning in Cervical Cancer Survivors (clinicaltrials.gov) - Jul 17, 2018
P=N/A, N=111, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=165 --> 111 | Trial completion date: Dec 2019 --> Jun 2018 | Trial primary completion date: Dec 2019 --> Jun 2018
- | tranexamic acid oral / Generic mfg.
Trial completion: Tranexamic Acid in Adolescents With Heavy Menstrual Bleeding (clinicaltrials.gov) - Jul 12, 2018
P4, N=32, Completed, Sponsor: Nationwide Children's Hospital
Active, not recruiting --> Completed | N=165 --> 111 | Trial completion date: Dec 2019 --> Jun 2018 | Trial primary completion date: Dec 2019 --> Jun 2018 Active, not recruiting --> Completed
- | Vagifem (estradiol) / Novo Nordisk
Phase classification: The Vaginal Health Trial (clinicaltrials.gov) - Jul 12, 2018
P3, N=302, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Phase classification: P4 --> P3
- | Enrollment closed, Trial primary completion date, Metastases: ADVISE: Advanced Methods for Cancer Detection by Vaginal Screening (clinicaltrials.gov) - Jul 11, 2018
P=N/A, N=120, Active, not recruiting, Sponsor: Anna Tinker
Phase classification: P4 --> P3 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2018 --> Aug 2018
- || Avastin (bevacizumab) / Roche
Trial completion, Trial completion date, Trial primary completion date, Metastases: Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors (clinicaltrials.gov) - Jul 10, 2018
P1, N=21, Completed, Sponsor: University of Alabama at Birmingham
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2018 --> Aug 2018 Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Jun 2018 | Trial primary completion date: Dec 2019 --> Apr 2018
- | Enrollment closed, Trial primary completion date: MRI-Guided Stereotactic Body Radiation Therapy (SBRT) for Ovarian Cancer (clinicaltrials.gov) - Jul 9, 2018
P1, N=10, Active, not recruiting, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Jun 2018 | Trial primary completion date: Dec 2019 --> Apr 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2018 --> May 2018
- | otesaconazole (VT-1161) / Mycovia Pharma
Phase classification: A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection) (clinicaltrials.gov) - Jul 6, 2018
P2a, N=55, Completed, Sponsor: Viamet
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2018 --> May 2018 Phase classification: P2 --> P2a
- | saracatinib (AZD0530) / AstraZeneca
Enrollment change, Metastases: AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Jul 3, 2018
P2, N=17, Completed, Sponsor: National Cancer Institute (NCI)
Phase classification: P2 --> P2a N=37 --> 17
- | davamotecan pegadexamer (EP0057) / Ellipses Pharma, Avastin (bevacizumab) / Roche
Trial completion, Combination therapy: CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer (clinicaltrials.gov) - Jul 2, 2018
P2, N=63, Completed, Sponsor: Massachusetts General Hospital
N=37 --> 17 Active, not recruiting --> Completed
- || Trial completion: Study of Axillary Skin Temperature as a Marker of Ovulation (clinicaltrials.gov) - Jun 27, 2018
P=N/A, N=10, Completed, Sponsor: Joanne Outtrim
Active, not recruiting --> Completed Recruiting --> Completed
- | Trial completion, Enrollment change: Outcomes of Uterine Rupture (clinicaltrials.gov) - Jun 27, 2018
P=N/A, N=65, Completed, Sponsor: Assiut University
Recruiting --> Completed Recruiting --> Completed | N=100 --> 65
- || quisinostat (JNJ 26481585) / ChemRar, Viriom
Trial completion, Combination therapy, BRCA Biomarker, Epigenetic controller, Metastases: Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy (clinicaltrials.gov) - Jun 27, 2018
P2, N=31, Completed, Sponsor: NewVac LLC
Recruiting --> Completed | N=100 --> 65 Active, not recruiting --> Completed
- ||| Trial completion, Trial completion date, Trial primary completion date, HEOR: HSCMyomecty: Effectiveness of Truclear on Patient Quality of Life (clinicaltrials.gov) - Jun 27, 2018
P=N/A, N=69, Completed, Sponsor: All For Women Healthcare, Illinois
Active, not recruiting --> Completed Recruiting --> Completed | Trial completion date: Sep 2017 --> May 2018 | Trial primary completion date: Aug 2017 --> Apr 2018
- | Trial completion: LO2: Evaluation of the Impact of Reduced Oxygen Concentration on Embryonic Development (clinicaltrials.gov) - Jun 27, 2018
P=N/A, N=60, Completed, Sponsor: Reproductive Medicine Associates of New Jersey
Recruiting --> Completed | Trial completion date: Sep 2017 --> May 2018 | Trial primary completion date: Aug 2017 --> Apr 2018 Active, not recruiting --> Completed
- | Trial completion, Enrollment change, Trial completion date: Infiltration of the Vestibulum Vaginae With Botulin Toxin in Patients With Localized Provoked Vulvodynia (clinicaltrials.gov) - Jun 25, 2018
P2, N=5, Completed, Sponsor: University Hospital, Ghent
Active, not recruiting --> Completed Recruiting --> Completed | N=50 --> 5 | Trial completion date: Jun 2016 --> Jun 2018
- | Trial completion: ROBO-GYN: Perioperative Morbidity in Gyneco-oncology According to the Procedure : Coelioscopy Versus Robot-assisted Coelioscopy (clinicaltrials.gov) - Jun 21, 2018
P=N/A, N=386, Completed, Sponsor: Centre Oscar Lambret
Recruiting --> Completed | N=50 --> 5 | Trial completion date: Jun 2016 --> Jun 2018 Active, not recruiting --> Completed
- || RG7882 / Roche
Trial completion: A Study Evaluating the Safety and Pharmacokinetics of DMUC4064A in Participants With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer (clinicaltrials.gov) - Jun 21, 2018
P1, N=35, Completed, Sponsor: Genentech, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Avastin (bevacizumab) / Roche
Trial completion date, Trial primary completion date: BOVARI: A Non-Interventional Study of Avastin (Bevacizumab) as Front-Line Treatment in Patients With Ovarian Cancer (clinicaltrials.gov) - Jun 19, 2018
P=N/A, N=63, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Trial completion date: May 2018 --> Sep 2018 | Trial primary completion date: May 2018 --> Sep 2018
- | Clinical data, Enrollment change, Trial withdrawal: An Exercise Intervention Trial to Reduce Symptoms & Improve Clinical Outcomes of Platinum-Based Treatment in Ovarian Cancer Patients (clinicaltrials.gov) - Jun 15, 2018
P=N/A, N=0, Withdrawn, Sponsor: City of Hope Medical Center
Trial completion date: May 2018 --> Sep 2018 | Trial primary completion date: May 2018 --> Sep 2018 N=10 --> 0 | Enrolling by invitation --> Withdrawn
- Trial termination: Effect of Saccharomyces Cerevisiae on Vulvo-vaginal Candidiasis (clinicaltrials.gov) - Jun 13, 2018
P=N/A, N=80, Terminated, Sponsor: Lesaffre International
N=10 --> 0 | Enrolling by invitation --> Withdrawn Recruiting --> Terminated; Recruitment difficulties
- Recentin (cediranib) / AstraZeneca, Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial completion, Trial completion date, PARP Biomarker: A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib (clinicaltrials.gov) - Jun 12, 2018
P2, N=4, Completed, Sponsor: University Health Network, Toronto
Recruiting --> Terminated; Recruitment difficulties Active, not recruiting --> Completed | Trial completion date: Jun 2019 --> Jun 2018
- | Avastin (bevacizumab) / Roche
Trial completion, Trial primary completion date: Autologous OC-DC Vaccine in Ovarian Cancer (clinicaltrials.gov) - Jun 11, 2018
P1, N=67, Completed, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Active, not recruiting --> Completed | Trial completion date: Jun 2019 --> Jun 2018 Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> May 2018
- || adavosertib (AZD1775) / AstraZeneca
Trial completion date, Trial primary completion date, Monotherapy, Metastases: Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours. (clinicaltrials.gov) - Jun 8, 2018
P1, N=62, Active, not recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> May 2018 Trial completion date: Apr 2018 --> Oct 2018 | Trial primary completion date: Nov 2017 --> Apr 2018
- | Trial completion: Effectiveness of Homeopathic Treatment in Female Infertility (clinicaltrials.gov) - Jun 6, 2018
P3, N=40, Completed, Sponsor: Fr Muller Homoeopathic Medical College
Trial completion date: Apr 2018 --> Oct 2018 | Trial primary completion date: Nov 2017 --> Apr 2018 Recruiting --> Completed
- | Phase classification, Enrollment change, Trial withdrawal, Trial primary completion date: PET Imaging of Ovarian Carcinoma With 18F-FSPG (clinicaltrials.gov) - Jun 6, 2018
P1, N=0, Withdrawn, Sponsor: Vanderbilt-Ingram Cancer Center
Recruiting --> Completed Phase classification: P=N/A --> P1 | N=20 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2018 --> Aug 2019
- | Trial completion date, Trial primary completion date: Fallopian Tube Removal as a Method of Ovarian Cancer Prevention: A Descriptive Study (clinicaltrials.gov) - Jun 4, 2018
P=N/A, N=24, Active, not recruiting, Sponsor: University of Washington
Phase classification: P=N/A --> P1 | N=20 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2018 --> Aug 2019 Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018
- | Trial completion: EC17 for Intraoperative Imaging in Occult Ovarian Cancer (clinicaltrials.gov) - Jun 4, 2018
P1, N=10, Completed, Sponsor: University of Pennsylvania
Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018 Active, not recruiting --> Completed
- | medroxyprogesterone injection / Generic mfg.
Trial completion, Adverse events: Drug Exposure and Depot Medroxyprogesterone Acetate (DMPA) in Adolescent Subjects (clinicaltrials.gov) - Jun 3, 2018
P3, N=34, Completed, Sponsor: Nationwide Children's Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Phase classification: OPUS: Outcomes Following Vaginal Prolapse Repair and Mid Urethral Sling Trial (clinicaltrials.gov) - Jun 3, 2018
P2, N=337, Completed, Sponsor: NICHD Pelvic Floor Disorders Network
Active, not recruiting --> Completed Phase classification: P3 --> P2
- Phase classification, Surgery: ExAblate Treatment of Uterine Fibroids for Fertility Enhancement (clinicaltrials.gov) - Jun 2, 2018
P=N/A, N=2, Terminated, Sponsor: InSightec
Phase classification: P3 --> P2 Phase classification: P4 --> P=N/A
- | Trial termination: YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy (clinicaltrials.gov) - Jun 2, 2018
P=N/A, N=2500, Terminated, Sponsor: Gynecologic Oncology Group
Phase classification: P4 --> P=N/A Active, not recruiting --> Terminated
- | Biomarker, Trial completion, Trial primary completion date: Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Jun 2, 2018
P=N/A, N=39, Completed, Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Terminated Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> Jan 2018
- | Enrollment closed, FDG PET: ERRICC: Diagnostic Performance of 18F-FDG-PET and Diffusion-weighted MRI in the Assessment of Stage IB to IIB2 Cervical Squamous-cell Carcinoma Response to Concomitant Radiochemotherapy and Brachytherapy (clinicaltrials.gov) - Jun 1, 2018
P=N/A, N=146, Active, not recruiting, Sponsor: Hospices Civils de Lyon
Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> Jan 2018 Recruiting --> Active, not recruiting
- | Myocet (non-pegylated liposomal doxorubicin) / Teva, Sopherion
Trial completion: Myocet (clinicaltrials.gov) - Jun 1, 2018
P1/2, N=87, Completed, Sponsor: ARCAGY/ GINECO GROUP
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Trial completion: Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer (clinicaltrials.gov) - Jun 1, 2018
P2, N=100, Completed, Sponsor: Ohio State University Comprehensive Cancer Center
Active, not recruiting --> Completed Recruiting --> Completed
- | Trial completion date, Trial primary completion date: EC-02: The Safety of Ovarian Preservation in Stage IA Endometrial Carcinoma (clinicaltrials.gov) - Jun 1, 2018
P=N/A, N=240, Recruiting, Sponsor: Ding Ma
Recruiting --> Completed Trial completion date: Dec 2018 --> Dec 2022 | Trial primary completion date: Dec 2017 --> Dec 2020
- | Trial completion: What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography (clinicaltrials.gov) - Jun 1, 2018
P1, N=49, Completed, Sponsor: University of Michigan
Trial completion date: Dec 2018 --> Dec 2022 | Trial primary completion date: Dec 2017 --> Dec 2020 Active, not recruiting --> Completed
- | BioAstin (astaxanthin) / Cyanotech
Trial primary completion date: Astax-ART: Oral Astaxanthin and Semen Quality, Fertilization and Embryo Development in Assisted Reproduction Techniques Procedures (clinicaltrials.gov) - May 31, 2018
P=N/A, N=80, Recruiting, Sponsor: University Medical Centre Ljubljana
Active, not recruiting --> Completed Trial primary completion date: Dec 2017 --> Jan 2019
- | Nexplanon (etonogestrel implant) / Organon
Enrollment closed: vMICROb: Long-Acting Progestin Contraception and the Vaginal Microbiome (clinicaltrials.gov) - May 4, 2018
P=N/A, N=35, Active, not recruiting, Sponsor: Boston Medical Center
Trial primary completion date: Dec 2017 --> Jan 2019 Recruiting --> Active, not recruiting
- | Phase classification: Musicotherapy in the Reduction of Fatigue in Women With Breast or Gynecological Cancer Under Radiotherapy (clinicaltrials.gov) - May 4, 2018
P=N/A, N=164, Completed, Sponsor: Universidade Federal de Goias
Recruiting --> Active, not recruiting Phase classification: P3 --> P=N/A
- | Trial completion date, Trial primary completion date: Yoga Practice for Breast or Ovarian Cancer Patients (clinicaltrials.gov) - May 4, 2018
P=N/A, N=39, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Phase classification: P3 --> P=N/A Trial completion date: Nov 2018 --> Nov 2019 | Trial primary completion date: Nov 2018 --> Nov 2019
- | Trial completion: MBPI: Mindfulness Based Program for Infertility (clinicaltrials.gov) - May 3, 2018
P=N/A, N=92, Completed, Sponsor: University of Coimbra
Trial completion date: Nov 2018 --> Nov 2019 | Trial primary completion date: Nov 2018 --> Nov 2019 Active, not recruiting --> Completed
- || Avastin (bevacizumab) / Roche
Trial completion date, Trial primary completion date: BOVARI: A Non-Interventional Study of Avastin (Bevacizumab) as Front-Line Treatment in Patients With Ovarian Cancer (clinicaltrials.gov) - May 2, 2018
P=N/A, N=63, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Trial completion date: Sep 2017 --> May 2018 | Trial primary completion date: Sep 2017 --> May 2018
- | Trial completion, Preclinical: Role of Heparin in Poor Responders Undergoing In Vitro Fertilisation (clinicaltrials.gov) - May 1, 2018
P2/3, N=50, Completed, Sponsor: National and Kapodistrian University of Athens
Trial completion date: Sep 2017 --> May 2018 | Trial primary completion date: Sep 2017 --> May 2018 Recruiting --> Completed